Insider buying last 90 days
No open-market insider purchases were filed for ALC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ALC insider filing, plotted on the chart in Gekko.Open ALC in Gekko
Gekko Brief
AI summaryNov 4 closeAlcon's stock advances this week on a mix of product and analyst news ahead of quarterly results. The company is developing a new digital platform aimed at streamlining cataract surgery, extending its technology focus beyond its existing Surgical and Vision Care portfolio, though the financial impact of this initiative is not yet clear. Separately, a study found that Systane PRO PF achieved non-inferiority against Miebo in patients with moderate-to-severe dry-eye symptoms, adding clinical support for Alcon's dry-eye line. Needham reiterated a Buy rating on Alcon with a price target of $98.
Shares close at $77.31, up 6.8%, sitting above both the 50-day average of $67.70 and the 200-day average of $71.88. The stock's one-month return stands at 22.3%, with three-month and six-month returns of 11.2% and 18.2% respectively, while the one-year return is 4.6%. The GekkoIndex reads 39.6, placing it in the Distribution zone, down 12.5 points over five sessions. Gekko Fair Value stands at $74.3, putting the current price 4.1% above that level.
Alcon reports next on 10 November 2026, five days away, a date that falls inside a typical 20-trading-day holding window; the prior quarter saw EPS of $0.84 against an estimate of $0.77, with a 4.9% reaction. Over the last 30 days, 2 unusual options signals appear, with call premium of $1,077,253 against put premium of $1,196,760. Seasonally, the next 20 trading days have averaged a 2.3% return over 5 years, rising in 2 of them. The consensus analyst target sits at $81.98, implying 6% upside.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Alcon price vs fair value
Close $77.31200-day averageGekko Fair Value $74.30
Alcon quick facts
- Market cap
- $37.37B
- P/E ratio
- 55.8
- Forward P/E
- 18.1
- EPS, TTM
- $1.32
- Revenue, TTM
- $10.86B
- Profit margin
- 5.9%
- Dividend yield
- 0.49%
- Beta
- 0.72
- Volume
- 3.75M avg 1.73M
- 1-year return
- +4.6%
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.6%
- 50-day average
- $67.70
- 200-day average
- $71.88
- Next earnings
- Nov 10
- Shares outstanding
- 483.4M
Alcon swing-trade checklist
Alcon scores 0 supportive, 3 mixed and 3 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
0 supportive3 mixed3 headwinds
- Trendmixed
Averages disagree
Close $77.31 sits between the 50-day ($67.70) and 200-day ($71.88) averages, or the averages disagree.
See the chart - GekkoIndexheadwind
39.6, Distribution
Reading 39.6 is in the Distribution zone.
See the GekkoIndex - Fair valuemixed
4.1% above
Price is within 5% of Gekko Fair Value (4.1% above).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 2 unusual options signals.
See smart money - Earnings riskheadwind
Reports in 5 days
Reports on Nov 10, 2026, 5 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+2.3% on average
From this point in the calendar, the next 20 trading days averaged +2.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Alcon stock chart and price history
Alcon closed at $77.31 on Nov 4, 2026, +4.6% over the past year, inside a 52-week range of $61.84 to $87.64.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +22.3%
- 3 months
- +11.2%
- 6 months
- +18.2%
- 1 year
- +4.6%
The full ALC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ALC in Gekko
Follow Alcon through every session
Put ALC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ALC in GekkoFree for 7 days. No credit card required.
About Alcon
Alcon develops and manufactures products used in eye care, ranging from surgical equipment to everyday vision correction items, and sells these worldwide. It is widely recognized for its work in cataract surgery, offering tools such as laser systems, biometers, digital markers, and implantable lenses, alongside instruments and disposable supplies used during procedures. Its offerings also extend to contact lenses and products addressing conditions like dry eye, allergies, and glaucoma.
The business is structured around two segments, Surgical and Vision Care. The Surgical side covers equipment, diagnostics, implants, and consumables used in operations such as cataract and vitreoretinal surgery, as well as tools for refractive procedures like LASIK. The Vision Care side focuses on contact lenses and ocular health products, including lens care solutions and vitamins for eye health.
Alcon traces its history back to 1945 and operated for a time under the name Alcon Universal S.A. before adopting its current name in December 2001. The company is headquartered in Geneva, Switzerland, and its shares are listed on the NYSE under the ticker ALC.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- alcon.com
Alcon GekkoIndex: the smart money zone
Alcon’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 39.6, in the Distribution zone, down 12.5 points over five sessions.
39.6Distribution
Down 12.5 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | +1.4% | +2.8% | ||
| Accumulation | 258 | −0.1% | +0.6% | ||
| Neutral | 375 | −0.1% | −1.0% | ||
| Distribution (current zone) | 25 | +0.3% | −1.0% | ||
| Selling | 1 | Too few readings yet | |||
Average ALC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the ALC price, zone by zone.Track ALC in Gekko
Is Alcon stock overvalued? Gekko Fair Value
Alcon trades 4.1% above Gekko Fair Value of $74.30, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Alcon shares are worth, recalculated every trading day.
$74.30
Gekko Fair Value, Nov 4, 2026
4.1% above fair value · About fair value
At the end of Aug 2026 the price was 7.5% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ALC in Gekko
Alcon insider and Congress trading
No open-market insider purchases were filed for Alcon, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ALC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ALC, plotted on the chart in Gekko.Open ALC in Gekko
Buybacks
Alcon has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $289.0M
- As a share of market cap
- 0.77%
- Trailing four quarters
- $921.0M
From company filings.
Unusual options activity last 30 days
2signals, 47% of the flagged premium in calls.
Latest: Bullish flow on Oct 16, $1.08M in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold ALC.
0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Alcon earnings: next date and track record
Alcon reports on Nov 10, 2026 (5 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 10, 2026
5 days away
- EPS estimate
- $0.89
- Revenue estimate
- $2.68B
6 of 8reports beat the EPS estimate
±6.6%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 10, 2026 AI summary
- What they said
- Alcon reported solid Q2 2026 results driven by new-product momentum and broad-based demand across franchises and geographies. Consolidated sales grew 7% to $2.8 billion with Surgical up 7% ($1.6B) driven by equipment (UNITY VCS/CS adoption and Valeda), implantables (IOLs up 2%, PanOptix Pro strong) and consumables growth. Vision Care grew 7% ($1.2B) led by contact lens share gains, pricing and ocular health (TRYPTYR and Systane’s multi-dose preservative-free). Equipment revenue rose 25% (UNITY adoption). Management highlighted the discontinuation of PowerVision IOL programs due to unpredictable postoperative outcomes, while reaffirming focus on tunable/accommodating IOL strategies and a strategic collaboration with RxSight. Management confirmed product approvals and rollouts (PanOptix Pro live in U.S./Europe; Vivity Pro submitted; TruPlus CE marked) and cited manufacturing improvements needed for UNITY DX before broader launch. Financially, management reiterated full-year revenue guidance of 5%–7% (constant currency) and discussed reinvesting a ~$40M tariff refund, share buybacks (lower share count), gross margins in the mid-60s (H1 ~64%), and a cost-efficiency program ($100M run-rate; ~$50M savings this year; ~$150M charges).
- Guidance
- Full-year 2026 revenue growth: 5%–7% (constant currency). Assumes aggregate markets grow ~3%–4%. Gross margin: H1 ~64% (tariff refund treated as one-time); expect higher gross margin in Q3 (if tariffs realized) and normalization/dip in Q4. EPS guidance: modestly raised at the midpoint (few pennies); drivers include tariff refund, share buybacks and one-time licensing income. Valeda peak sales potential: $100M–$150M in ~3–5 years. Equipment market: 30,000 units over ~10 years (earlier cadence accelerated).
- Risks flagged
- Discontinuation of PowerVision IOL programs (technology/clinical risk). Competitive pressure in IOLs and contact lenses (new competing launches). Reimbursement headwinds and slower adoption in surgical glaucoma (Hydrus) and broader macro/market headwinds (U.S. cataract procedural variability). Manufacturing and scalability issues for new products (UNITY DX). Dependence on tariff refund (one-time benefit) and one-time licensing income impacting reported margins/earnings.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | $0.84 est $0.77 | $2.78B est $2.72B | +4.9% |
| May 5, 2026 | $0.85 est $0.83 | $2.62B est $2.64B | −11.0% |
| Feb 24, 2026 | $0.78 est $0.78 | $2.64B est $2.69B | +4.1% |
| Nov 11, 2025 | $0.79 est $0.77 | $2.61B est $2.71B | +6.8% |
| Aug 19, 2025 | $0.76 est $0.71 | $2.60B est $2.65B | −8.0% |
| May 13, 2025 | $0.73 est $0.76 | $2.47B est $2.63B | −8.0% |
| Feb 25, 2025 | $0.57 est $0.47 | $2.50B est $2.47B | +4.5% |
| Nov 12, 2024 | $0.81 est $0.74 | $2.45B est $2.46B | −5.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Alcon stock forecast and analyst price targets
Analysts’ average 12-month price target for Alcon is $81.98, +6.0% from the last close.
$81.98consensus 12-month target, +6.0% from the last close
−1.0%average 20-day move after past Distribution readings
+2.3%average move over the next 20 trading days in the last 5 years
±2.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Alcon seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Alcon averaged +2.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.3% | 3 of 5 |
| Next 10 trading days | +0.2% | 2 of 5 |
| Next 15 trading days | +1.5% | 2 of 5 |
| Next 20 trading days | +2.3% | 2 of 5 |
| Next 30 trading days | +3.1% | 3 of 5 |
For scale, ALC’s typical 20-trading-day move in either direction is about 4.6%.
Alcon market cap and key statistics
Alcon’s market cap is $37.37B, with a P/E ratio of 55.8 and revenue of $10.86B over the last twelve months.
Valuation
- Market cap
- $37.37B
- P/E ratio
- 55.8
- Forward P/E
- 18.1
- EPS, TTM
- $1.32
- Gekko Fair Value
- $74.30
Trading
- Volume
- 3.75M
- Avg volume, 20 days
- 1.73M
- 52-week high
- $87.64
- 52-week low
- $61.84
- Shares outstanding
- 483.4M
Financials
- Revenue, TTM
- $10.86B
- Profit margin
- 5.9%
- Return on equity
- 2.9%
- Quarterly earnings growth, YoY
- −44.6%
Risk and income
- Beta
- 0.72
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.6%
- Dividend yield
- 0.49%
Alcon stock news this week
Coverage of Alcon this week reads positive: 6 positive, 4 neutral and 1 negative headlines.
- Alcon stock gains digital platform angle ahead of resultsad-hoc-news.de, Nov 4
- Alcon Inc. (ALC) stock price, news, quote and historyYahoo Finance Australia, Nov 4
- Alcon stock turns to digital platform for cataract surgeryad-hoc-news.de, Nov 4
- Needham maintains Alcon at Buy, keeps price target at $98TradingView, Nov 2
- Alcon stock gains clinical support from Systane studyad-hoc-news.de, Nov 2
- Alcon Inc. (ALC.SW) Seasonal returns chartYahoo Finance UK, Nov 2
Alcon peers
Alcon’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
A peer links to its own page where one exists.
Alcon stock FAQ
What is Alcon’s market cap?
Alcon’s market cap is $37.37B at the Nov 4, 2026 close of $77.31, with 483.4M shares outstanding. The shares trade on a P/E ratio of 55.8.
What is the Alcon stock forecast?
The consensus analyst 12-month price target for Alcon is $81.98, +6.0% from the last close. Gekko doesn’t publish price predictions of its own.
Is Alcon stock overvalued or undervalued?
On Gekko’s estimate Alcon is about fair value: the Nov 4, 2026 close of $77.31 is 4.1% above Gekko Fair Value of $74.30. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Alcon report earnings next?
Alcon is expected to report on Nov 10, 2026 (5 days away). Analysts expect earnings of $0.89 per share on revenue of $2.68B. Alcon beat the earnings estimate in 6 of its last 8 reports, moving 6.6% on average across the report.
What is Alcon’s 52-week high and low?
Alcon’s 52-week high is $87.64 and its 52-week low is $61.84; it closed at $77.31 on Nov 4, 2026, +4.6% over the past year. Over the last five years the shares peaked at $101.10 on Sep 12, 2024.
Is Alcon stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 0 of the 6 items with data read as supportive, 3 as mixed (trend, fair value and seasonality) and 3 as headwinds (gekkoindex, smart money and earnings risk). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Alcon?
Gekko flagged 2 unusual options signals in Alcon over the last 30 days, with $1.08M of flagged premium in calls and $1.20M in puts. The latest, bullish flow, was on Oct 16, 2026 with $1.08M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Alcon the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.